Adaptive Biotechnologies vs Immunocore
ADPT and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADPT and IMCR compare
Adaptive Biotechnologies is the larger company, worth 3.0 times as much as Immunocore ($4.6B against $1.5B).
Adaptive Biotechnologies grew revenue faster over the last twelve months (17.9% versus 13.1% for Immunocore).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −23.7% at Adaptive Biotechnologies.
Adaptive Biotechnologies scores higher on the StockData Score (12 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADPT | IMCR |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $1.5B |
| Share price | $29.04 | $29.94 |
| Change, 1 year | 100% | −15.2% |
| Change, 5 years | 6.2% | −21.4% |
| Beta (5Y) | 1.79 | 0.69 |
| Employees | 624 | 524 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.6× | 3.6× (better) |
| P/B | 26.3× | 3.7× (better) |
| FCF yield | −0.19% (better) | −1.2% |
| Fair value | $6.88 | $31.07 |
| Margin of safety | −322% | 3.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 17.9% (better) | 13.1% |
| Revenue growth, 5Y average | 23.0% | – |
| Profitability | ||
| Gross margin | 74.2% | 98.9% (better) |
| Operating margin | −16.2% | −6.8% (better) |
| Net margin | −23.7% | −7.5% (better) |
| FCF margin | −3.0% (better) | −4.2% |
| Return on equity | −37.1% | −7.9% (better) |
| Return on invested capital | −9982% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −5.3× | −2.4× (better) |
| Current ratio | 3.97 | 4.62 (better) |
| Altman Z-score | 3.38 (better) | 1.45 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.6% | 102% |
| Held by insiders | 22.7% | 15.5% |
| Insider net buying, 12 months | −$117M | −$1.9M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | – |
Go deeper
- ADPT stock overview
- ADPT income statement
- ADPT valuation and score
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.